[미국특허]
Jucara and Açai fruit-based compositions
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-036/889
A23L-001/212
A23L-001/30
A61K-009/00
출원번호
US-0726221
(2015-05-29)
등록번호
US-9526755
(2016-12-27)
발명자
/ 주소
Murdock, Kenneth A.
Schauss, Alexander G.
출원인 / 주소
Murdock, Kenneth A.
대리인 / 주소
Hassid, Steve P.
인용정보
피인용 횟수 :
0인용 특허 :
3
초록▼
The present invention relates to stable, palatable, freeze-dried, fruit-based compositions. Specifically, the inventions relates to compositions of Açai fruit and Jucara fruit with high antioxidant capability and cyclooxygenase-inhibitory activity, and their uses. The invention further provides for
The present invention relates to stable, palatable, freeze-dried, fruit-based compositions. Specifically, the inventions relates to compositions of Açai fruit and Jucara fruit with high antioxidant capability and cyclooxygenase-inhibitory activity, and their uses. The invention further provides for methods of making stable, palatable, freeze-dried, fruit-based compositions from Açai fruit and Jucara fruit.
대표청구항▼
1. An oral composition comprising freeze-dried açai fruit pulp and a pharmaceutically acceptable carrier, wherein the freeze-dried açai fruit pulp prior to being combined with the pharmaceutically acceptable carrier was frozen at a temperature of −5° C. or less, and has an anthocyanin concentration
1. An oral composition comprising freeze-dried açai fruit pulp and a pharmaceutically acceptable carrier, wherein the freeze-dried açai fruit pulp prior to being combined with the pharmaceutically acceptable carrier was frozen at a temperature of −5° C. or less, and has an anthocyanin concentration greater than 0.5 milligram per gram total weight and an ORACFL value greater than about 350 micromole TE per gram total weight; and wherein the oral composition is contained in a capsule, tablet or caplet. 2. The oral composition of claim 1, wherein the pharmaceutically acceptable carrier comprises one or more of a binder, an excipient, a lubricant, a flavoring compound and a sweetening agent. 3. The oral composition of claim 1, wherein the pharmaceutically acceptable carrier comprises a binder, an excipient and a sweetening agent. 4. The oral composition of claim 1, wherein the binder is selected from the group consisting of cellulose and gum, and the excipient is selected from the group consisting of starch and lactose. 5. The oral composition of claim 1, wherein the pharmaceutically acceptable carrier comprises: cellulose, gum, starch, and a sweetening agent. 6. The oral composition of claim 1, wherein the pharmaceutically acceptable carrier comprises ascorbic acid. 7. An oral composition comprising freeze-dried juçara fruit pulp and a pharmaceutically acceptable carrier, wherein the freeze-dried juçara fruit pulp prior to being combined with the pharmaceutically acceptable carrier was frozen at a temperature of −5° C. or less, and has an anthocyanin concentration greater than 0.5 milligram per gram total weight and an ORACFL value greater than about 350 micromole TE per gram total weight; and wherein the oral composition is contained in a capsule, tablet or caplet. 8. The oral composition of claim 7, wherein the pharmaceutically acceptable carrier comprises one or more of a binder, an excipient, a lubricant, a flavoring compound and a sweetening agent. 9. The oral composition of claim 7, wherein the pharmaceutically acceptable carrier comprises a binder, an excipient and a sweetening agent. 10. The oral composition of claim 7, wherein the binder is selected from the group consisting of cellulose and gum, and the excipient is selected from the group consisting of starch and lactose. 11. The oral composition of claim 7, wherein the pharmaceutically acceptable carrier comprises: cellulose, gum, starch, and a sweetening agent. 12. The oral composition of claim 7, wherein the pharmaceutically acceptable carrier comprises ascorbic acid. 13. An oral composition comprising a mixture of freeze-dried juçara fruit pulp and freeze-dried açai fruit pulp and a pharmaceutically acceptable carrier, wherein the mixture prior to being combined with the pharmaceutically acceptable carrier was frozen at a temperature of −5° C. or less, and has an anthocyanin concentration greater than 0.5 milligram per gram total weight and an ORACFL value greater than about 350 micromole TE per gram total weight; and wherein the oral composition is contained in a capsule, tablet or caplet.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.